Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2021 | ARROW: PSMA-targeted radioligand therapy plus enzalutamide in mCRPC

Frédéric Pouliot • 15 Feb 2021
GU Cancers 2021
Genitourinary Cancer Prostate Cancer 131I-MIP-1095 Abiraterone Enzalutamide
ARROW

Frédéric Pouliot, MD, PhD, FRCSC, University Hospital of Quebec and Laval University, Quebec, Canada, shares an update on the Phase II ARROW (NCT03939689) trial at ASCO GU 2021. The ARROW trial is a randomized trial investigating the efficacy and safety of the prostate-specific membrane antigen (PSMA)-targeted 131I-MIP-1095 plus enzalutamide compared to enzalutamide alone, in patients with metastatic castration-resistant prostate cancer (mCRPC) who are chemotherapy naïve and have progressed on abiraterone. This interview took place during the 2021 Genitourinary Cancers Symposium.

More from Frédéric Pouliot

PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients with prostate cancer
4:42
PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients with prostate cancer
Frédéric Pouliot • 4 Jun 2021
18F-DCFPyL PET/CT imaging up-stages patients with prostate cancer
3:13
18F-DCFPyL PET/CT imaging up-stages patients with prostate cancer
Frédéric Pouliot • 15 Feb 2021
Role of steroids in sustaining castration resistance
1:25
Role of steroids in sustaining castration resistance
Frédéric Pouliot • 13 Feb 2020
OSPREY: PSMA-targeted PET-CT imaging in prostate cancer
2:02
OSPREY: PSMA-targeted PET-CT imaging in prostate cancer
Frédéric Pouliot • 13 Feb 2020

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals